Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
Luminice-203 yields its first topline data, but where are all the patients?
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
Pfizer moves to take PF-07934040 into its first clinical trial.
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
Supply continues to cause headaches for radiopharmaceutical developers.